Efficacy of dose-dense chemotherapy as first-line treatment of advanced ovarian cancer patients after non-optimal debulking.

被引：0
|
作者：
Rumyantsev, Alexey
Tyulyandina, Alexandra
Pokataev, Ilya
Morkhov, Konstantin
Nechuskina, Valentina Mikhailovna
Tjulandin, Sergei
机构：
[1] Minist Hlth Russian Federat NN Blokhin NMRCO, Fed State Budgetary Inst, NN Blokhin Natl Med Res Ctr Oncol, Moscow, Russia
[2] Russian Canc Res Ctr, Moscow, Russia
[3] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18066
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dose-dense first-line chemotherapy in advanced ovarian cancer: How to select the patients?
    Tjulandina, Alexandra
    Stenina, Marina
    Pokataev, Ilya
    Fedyanin, Mikhail
    Tryakin, Alexey
    Tjulandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer
    Zhang, Li
    Zhou, Qi
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 837 : 64 - 71
  • [3] EFFICACY AND SAFETY OF TC DOSE-DENSE CHEMOTHERAPY IN FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER; A RETROSPECTIVE COHORT STUDY IN THE SINGLE INSTITUTION
    Vrdoljak, J.
    Boban, T.
    Mise, B. Petric
    Jelavic, T. Boraska
    Bajic, Z.
    Tomic, S.
    Vrdoljak, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 866 - 866
  • [4] Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer
    Fleming, Nicole D.
    Coleman, Robert L.
    Tung, Celestine
    Westin, Shannon N.
    Hu, Wei
    Sun, Yunjie
    Bhosale, Priya
    Munsell, Mark F.
    Sood, Anil K.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 41 - 46
  • [5] Phase II trial of bevacizumab with carboplatin and dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer
    Fleming, N. D.
    Coleman, R. L.
    Tung, C. S.
    Munsell, M. F.
    Sood, A. K.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 79 - 79
  • [6] Dose-dense chemotherapy in advanced ovarian cancer
    Bookman, Michael A.
    LANCET, 2009, 374 (9698): : 1303 - 1305
  • [7] Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study
    Vrdoljak, J.
    Boban, T.
    Mise, B. Petric
    Jelavic, T. Boraska
    Bajic, Z.
    Tomic, S.
    Vrdoljak, E.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (04) : 347 - 353
  • [8] A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer
    Komazaki, Hiromi
    Takahashi, Kazuaki
    Tanabe, Hiroshi
    Shoburu, Yuichi
    Kamii, Misato
    Tsuda, Akina
    Saito, Motoaki
    Yamada, Kyosuke
    Takano, Hirokuni
    Michimae, Hirofumi
    Okamoto, Aikou
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (06)
  • [9] Controversies on the treatment of ovarian cancer with dose-dense chemotherapy
    Suarez-Zaizar, Alberto
    Cardenas-Cardenas, Eduardo
    Araceli Barajas-Castro, Yadira
    Cortes-Esteban, Patricia
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [10] A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma
    Rettenmaier, Mark A.
    Micha, John P.
    Bohart, Randy
    Goldstein, Bram H.
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2020, 244 : 101 - 105
12345